破解“最后一公里”！商业健康险助力创新药，如何布局？

Core Viewpoint - The article emphasizes the significant role of commercial health insurance in promoting the development of innovative drugs and medical devices, highlighting its potential to alleviate patients' financial burdens and enhance the accessibility of high-value medical services [1][3][4]. Group 1: Development of Commercial Health Insurance - The government report during the Two Sessions called for accelerating the development of commercial health insurance to better meet diverse medical needs [1][2]. - The insurance industry sees the government's focus on commercial health insurance as an opportunity to stimulate market participants to enhance its development and facilitate medical innovation [2][3]. - Commercial health insurance is viewed as a crucial component of a multi-tiered medical security system, effectively addressing the economic pressures faced by patients [2][3]. Group 2: Challenges in Implementation - Despite the establishment of the commercial health insurance innovative drug directory, challenges remain in the practical application of innovative drugs, particularly in hospitals [6][7]. - Issues such as the "last mile" problem, where innovative drugs face difficulties in hospital access and prescription availability, hinder their effective use [6][7]. - The lack of clinical guidelines and the limited willingness of hospitals to adopt these drugs contribute to the low utilization rates of the commercial health insurance directory drugs [6][7]. Group 3: Financial Implications and Market Dynamics - In 2024, the total compensation amount for innovative drugs under commercial health insurance is projected to be approximately 12.4 billion yuan, with a significant portion coming from government-led initiatives [4]. - The introduction of the commercial health insurance innovative drug directory allows for a dual-track payment system, where commercial insurance complements basic medical insurance by covering high-value innovative drugs [5][6]. - The insurance industry faces challenges in pricing and risk management due to a lack of comprehensive data on innovative drugs, which complicates the development of related insurance products [8][9]. Group 4: Recommendations for Improvement - Suggestions include accelerating the inclusion of public hospitals in the commercial health insurance innovative drug directory and establishing a dynamic adjustment mechanism for the directory [9][10]. - Enhancing the payment levels of commercial health insurance for innovative drugs is crucial, with recommendations for reforming funding models and improving efficiency [10][11]. - The establishment of a collaborative governance model involving insurance companies in the development of clinical guidelines for high-value innovative drugs is proposed to improve accessibility and affordability [9][10].